How Peptides Accelerate Healing: BPC-157, TB-500, and Pinealon Explained

James Odell, OMD, ND,L.Ac

So, What Exactly Is a Peptide?

Peptides are strings of amino acids, which are the "building blocks" of proteins. The fundamental difference between proteins and peptides lies in their length: most scientists refer to chains with more than 40–50 amino acids as proteins, while shorter chains are classified as peptides.

Peptides are generally categorized according to the number of amino acids they contain. For example, a peptide composed of just two amino acids is termed a "dipeptide," while one with three amino acids is called a "tripeptide." The word "peptide" itself derives from the Greek word meaning "to digest."

Peptides are an essential part of nature and biochemistry, acting as messengers who instruct the body to regulate specific biological processes. Because of their highly specific nature, peptides allow for precisely targeted therapies ranging from recovery and repair, metabolic function, and longevity applications, all while minimizing side effects more than traditional treatments, which tend to affect multiple systems at once.  Thousands of peptides occur naturally in the human body and in animals, and new peptides are being discovered and synthesized regularly in research laboratories. This ongoing discovery and innovation in peptide science holds great promise for the future of healthcare and biochemical development.

And, What Is a Bioregulator?

"Bioregulators" represent a specialized subset of peptides. These ultra-short peptides (containing only 2–4 amino acids) act as specific DNA-targeting messengers, influencing gene expression to promote cellular repair and slow aging. Unlike general peptides that often work on cell surfaces for faster effects—such as hormone regulation or muscle building—bioregulators offer deeper, long-term rejuvenation by working directly inside the cell, turning on beneficial genes and turning off aging-related ones. They often function organ-specifically, and research suggests significant anti-aging potential, though proper guidance is crucial for their use.

Cycle lengths for bioregulators are typically short term, while use of longer-chain peptides can vary to extended cycles. Bioregulators recalibrate cells to their baseline regulatory state, restoring them from age-related dysfunction homeostasis.  

Numerous peptides and bioregulators are being studied and used clinically today. For brevity, this article will introduce two peptides and one bioregulator. For readers seeking more comprehensive information on peptides and bioregulators, Peptide Sciences (https://www.peptidesciences.com/) maintains an excellent website describing dozens of peptides and serves as a leading provider of research peptides.

From Insulin to Innovation: The Evolution of Peptide Therapy

The first half of the 20th century witnessed the discovery of several life-saving bioactive peptides, including insulin and adrenocorticotrophic hormone, which were initially studied and isolated from natural sources. The discovery and development of insulin—a peptide with 51 amino acids—has been considered one of the monumental scientific achievements in drug discovery. 

Research into therapeutic peptides began with fundamental studies of natural human hormones, including insulin, oxytocin, vasopressin, and gonadotropin-releasing hormone, and their specific physiological activities in the human body.

Since the synthesis of the first therapeutic peptide, insulin, in 1921, remarkable achievements have been made, resulting in the approval of more than 100 peptide compounds worldwide. Peptide discovery has diversified beyond its traditional focus on endogenous human peptides to now include a broader range of structures identified from other natural sources or through medicinal chemistry efforts.

The field of peptide and bioregulator therapy is vast, and books are constantly being written and updated on the subject. This article will outline a few of the more commonly studied experimental peptides and bioregulators.

Navigating the Regulatory Landscape: What You Need to Know

Dozens of synthetic peptides and bioregulators are now commercially available, though many are not FDA-approved. It should be noted that doctors prescribing or recommending FDA-unapproved peptides operate in a regulatory gray zone. Without FDA approval, prescribing such substances could be considered malpractice, risking their licenses and potential legal action. Healthcare providers have an ethical obligation to prioritize patient safety and provide informed consent.

Without FDA approval, there is no regulatory oversight on the manufacturing of these synthetic peptides. This lack of regulation raises concerns about product purity, dosage accuracy, and contamination with harmful substances. As with any peptide, adverse effects are possible, most often due to unregulated manufacturing and contamination. It is recommended to use only peptides and bioregulators from sources that employ the strictest purification practices in the industry, particularly those that use third-party testing for purity and potency.

That said, this article is for research information purposes only and should not be construed as a guide for peptide or bioregulator administration for any medical condition.

BPC-157: The Body's Natural Protector, Amplified

Known as Body Protection Compound 157, BPC-157 is a synthetic peptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It represents a fragment of the body's endogenous protection compound found in gastric juice. First described in 1992, BPC-157 is a naturally occurring peptide in gastric juices that endogenously functions to promote gastric mucosal integrity and homeostasis.

BPC-157 works primarily by promoting angiogenesis—the process through which new blood vessels form from pre-existing vessels. This mechanism can significantly enhance the body's ability to repair tissues and reduce inflammation. Data also suggests that it influences cytoprotective signaling through modulation of nitric oxide pathways, growth factor expression, and extracellular matrix remodeling.

Increasingly, BPC-157 is being studied in a variety of disease states due to its proposed angiogenic, anti-inflammatory, and wound-healing properties. In preclinical models, BPC-157 demonstrates significant cytoprotective effects across a range of organs and tissues, including the alimentary canal, liver, pancreas, heart, and nerves. The compound also shows promise in the rapid healing of muscles, bones, and joints, which highlights its potential application in orthopedic sports medicine. Notably, there appear to be little to no adverse effects reported in preclinical literature.

Preclinical studies demonstrate its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries. Despite lacking US-FDA approval and its use being banned in professional sports, BPC-157 is increasingly being used by clinicians and athletes alike.

Most peptides are administered as injectables, as orally administered peptides and bioregulators may be denatured by the hydrochloric acid in the stomach and proteolytic enzymes of the pancreas, resulting in limited bioavailability. BPC-157 is an exception, however,  as it’s available in oral form, although efficacy is primarily limited to the intestinal tract rather than systemic regeneration . It is often recommended to purchase the oral form compounded with the arginine salt for improved stability and bioavailability. Oral formulations are designed for direct, systemic absorption through the digestive tract.

The following represents a typical dosage range. As with any drug or supplement, dosage must be tailored to the individual and administered under the supervision of a clinical professional who is well-versed in peptides. Although injectable forms are available for research purposes, many prefer oral BPC-157 due to its convenience.

Common Formulas and Protocols:

• BPC-157 (10mg) Lyophilized vial: 200-500 mcg subcutaneous injection daily for 8 weeks. Often administered in split doses, (250 mcg, morning and night.) 

• BPC-157 (500 mcg) Capsule: one capsule daily for 30 days

• BPC-157 (500 mcg) Sublingual Troche: one troche daily for 30 days

• BPC-157 (500 mcg) Suppository: one suppository daily for 30 days

• BPC-157 (1mg/g) Anti-inflammatory cream: Apply ¼ g–1 gram daily for 30 days

For more detailed information on BPC-157 dosage and use, consult: https://nulevelwellnessmedspa.com/bpc-157-dosage/

Combining BPC-157 with other peptides—a practice known as "stacking"—can target specific tissues and enhance results. One common combination is BPC-157 with TB-500 for tissue and tendon repair.

TB-500: Harnessing Your Thymus for Tissue Regeneration

TB-500 is a 43-amino acid sequence synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a key role in wound healing, cell differentiation, and tissue regeneration. 

Thymosins are a type of hormone-like polypeptide produced by the thymus, a small gland located behind the sternum that produces most of the body's T lymphocytes—white blood cells that help the immune system function properly to destroy pathogens and even cancer cells. The thymus is an integral part of the immune system, serving as the site where T cells are made to respond to millions of pathogenic bacteria, fungi, and microorganisms that invade the body.

Thymosin Beta-4, first isolated in the 1960s, is known as an excellent immune modulator. This cell-building protein is an essential component of cell structure and movement, which assists in joint, tissue, muscle, and ligament repair. It promotes angiogenesis, collagen deposition, and cell migration to speed up recovery from soft tissue injuries. Some studies show it reduces inflammation and pathogenic microbial growth. Researchers also note that TB4 is critical for the repair and regeneration of eye, heart, skin, nerve, and brain tissue after injury.

Pivoting to TB-500, it is based on a single one of the "active sites" of TB4—the peptide segment responsible for the compound's actin-binding and cell migration abilities. Since most of TB4's potential benefits are attributed to its actin-binding properties, it can be assumed that the same applies to TB-500. However, this is mainly an assumption at this point in time, as there is not very much research on TB-500 itself; most research focuses on TB4.

Like BPC-157, TB-500 is not approved by the US FDA for any medical use in humans. It is sold for experimental use only.

Potential Healing Benefits and Effects of Peptides

• Enhanced Tissue Repair: Promotes healing of muscles, tendons, ligaments, and skin.

• Angiogenesis: Stimulates the formation of new blood vessels, aiding tissue regeneration.

• Anti-inflammatory: Reduces inflammation, protecting tissues from further damage.

• Flexibility: Known for improving range of motion and reducing soft tissue discomfort.

• Muscle Regeneration: Studies suggest improved muscle fiber regeneration.

  
  

The following are typical formulas and dosage ranges. As with any drug or supplement, dosage must be tailored to the individual and administered under the supervision of a clinical professional who is well-versed in peptides.

• Thymosin Alpha-1 (15 mg) Vial: 500-1000 mcg subcutaneous injection daily for 4-8 weeks. Often split in 2 doses of 250 mcg morning and night. 

• Thymosin Alpha-1 (2000 mcg/ml) nasal spray 15 ml bottle: 200 mcg (1–2 sprays) each nostril daily

• Oral form of TB-500 called TB4-Frag 500: 500 mg capsule twice daily for 30 days

BPC-157 is often combined with TB-500 due to each peptide's complementary effects on angiogenesis and cellular/tissue regeneration.

Pinealon: Unlocking Brain Longevity at the Genetic Level

Pinealon is a synthetic tripeptide, or bioregulator, (Glu-Asp-Arg) that has been investigated for its potential to regulate neuronal differentiation and oxidative-stress responses. Preclinical models demonstrate its influence on mitochondrial enzyme activity, neuroprotective signaling, and gene expression linked to synaptic plasticity. Pinealon is primarily known for its neuroprotective and cognitive-enhancing properties.

Originally developed in Russia as a bioregulator, Pinealon acts by reducing oxidative stress, supporting brain cell repair, enhancing neuroplasticity, and regulating circadian rhythms. It is primarily studied for its potential to reverse age-related cognitive decline, and has also been used in rehabilitation after strokes, traumatic brain injuries and during periods of stress and high mental workload. 

Pinealon also appears to extend cellular lifespans via telomere lengthening. Telomeres are protective "caps" of DNA sequences at the ends of chromosomes. They shorten every time a cell divides and eventually reach the point at which proper cell division is no longer possible, resulting in cellular senescence. Senescent cells, in turn, can contribute to various age-related diseases, including cancer, atherosclerosis, osteoarthritis, and cognitive decline.

Potential Benefits and Effects

• Neuroprotection: Studies show Pinealon protects against neural cell death (apoptosis) and reduces ROS (reactive oxygen species) accumulation.

• Cognitive Support: Used to enhance brain function, including memory and focus.

• Circadian Rhythm Regulation: Aids in supporting natural sleep patterns; often used alongside other peptides like Epitalon.

• Anti-Aging (Geroprotector): Has demonstrated an ability to slow down age-related changes in the central nervous system.

• Direct DNA Action: Research indicates Pinealon may penetrate cell nuclei to influence gene expression and protein synthesis.

The following are typical formulas and dosage ranges. As with any drug or supplement, dosage must be tailored to the individual and administered under the supervision of a clinical professional who is well-versed in peptides.

Common research doses range from 100–300 mcg per injection via subcutaneous injection or, in some cases, nasal sprays or oral solutions. Administration is typically once daily or every other day. Pinealon is often cycled, with 10–20 days on followed by 2–3 months off.

Important Note: Don't overstimulate the system. This isn't a daily forever regimen, but rather a tool to support your brain's healing mechanisms, and then step back and let the body do the rest.

The Future is Peptides: Where We Go From Here

Peptide therapeutics have played a notable role in medical practice since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are currently approved in the United States and other major markets, and many more continue to enter clinical development at a steady pace. Not surprisingly, the areas of highest concentration for peptide development at present are fields of high interest, such as metabolic disease, oncology, cardiovascular disease, and longevity.

Efforts are underway to improve the oral availability of peptide therapeutics by increasing drug stability in the gastrointestinal tract, formulating peptides with permeability enhancers, and improving the central nervous system availability of peptides through conjugation to carrier molecules or delivery in nanoparticles.

From humble beginnings as substances isolated from livestock glands, peptides have established a unique therapeutic place in healthcare and will continue to be an important element in the bioregulatory medicine landscape.

References

Bako, P., Lippai, B., Nagy, J., Kramer, S., Kaszas, B., Tornoczki, T., & Bock-Marquette, I. (2023). Thymosin beta-4 – A potential tool in healing middle ear lesions in adult mammals. International Immunopharmacology, 116, 109830.

I, Balenovic D, Udovicic M, et al. Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats. Biomedicines. 2022;10(2):265. [DOI] [PMC free article] [PubMed] [Google Scholar]

Belsky, J. B., Rivers, E. P., Filbin, M. R., Lee, P. J., & Morris, D. C. (2018). Thymosin beta 4 regulation of actin in sepsis. Expert Opinion on Biological Therapy, 18(SUP1), 193.

Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol Off J Pol Physiol Soc. 2009;60(Suppl 7):191–196. [PubMed] [Google Scholar]

Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28:1155–1161. [DOI] [PubMed] [Google Scholar]

Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066–19077. [DOI] [PMC free article] [PubMed] [Google Scholar]

Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–780. [DOI] [PubMed] [Google Scholar]

Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37–51.

Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377:153–159. [DOI] [PubMed] [Google Scholar]

Ho, E. N., Kwok, W., Lau, M., Wong, A. S., Wan, T. S., Lam, K. K., Schiff, P. J., & Stewart, B. D. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry.

Journal of Chromatography A, 1265, 57-69.

Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485–2499. [DOI] [PMC free article] [PubMed] [Google Scholar]

Karantysh, G. V., M. P. Fomenko, A. M. Menzheritskii, V. N. Prokof'ev, G. A. Ryzhak, and E. V. Butenko. "Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes." Neurochemical Journal 14, no. 3 (2020): 314-320.

Khavinson, V., Y. Ribakova, K. Kulebiakin, E. Vladychenskaya, L. Kozina, A. Arutjunyan, and A. Boldyrev. "Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes." Rejuvenation Research 14, no. 5 (2011): 535-541.

Kozina, L. S., A. V. Arutjunyan, S. L. Stvolinskii, M. S. Stepanova, M. G. Makletsova, and V. Kh Khavinson. "Regulatory peptides protect brain neurons from hypoxia in vivo." In Doklady Biological Sciences, vol. 418, no. 1, p. 7. Springer Nature BV, 2008.

Kleinman, H., & Sosne, G. (2016). Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 102, 251-275.

Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. J Orthop Res. 2006;24:982–989. [DOI] [PubMed] [Google Scholar]

Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res. 2008;57:205–210. [DOI] [PubMed] [Google Scholar]

Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg. 2019;14:199. [DOI] [PMC free article] [PubMed] [Google Scholar]

Perovic D, Milavic M, Dokuzovic S, et al. Novel therapeutic effects in rat spinal cord injuries: recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy. Curr Issues Mol Biol. 2022;44:1901–1927. [DOI] [PMC free article] [PubMed] [Google Scholar]

Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A. L., & Kleinman, H. K. (2003). Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19-24.

PLANS, BONS. "Pinealon Peptide: Potential in Cellular Vitality and Cellular Aging Research."

Severa, M., Zhang, J., Giacomini, E., Rizzo, F., Etna, M. P., Cruciani, M., Garaci, E., Chopp, M., & Coccia, E. M. (2019). Thymosins in multiple sclerosis and its experimental models: Moving from basic to clinical application. Multiple Sclerosis and Related Disorders, 27, 52-60.

Shah, R., Reyes-Gordillo, K., Cheng, Y., Varatharajalu, R., Ibrahim, J., & Lakshman, M. R. (2018). Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxidative Medicine and Cellular Longevity, 2018(1), 9630175.

Sikirić P, Petek M, Rotkvić I, et al. Antiulcerogenic and anti-inflammatory effect of a new gastric juice peptide-body protection compound. Exp Clin Gastroenterol. 1991;1:179–181. [Google Scholar]

Skorjanec S, Kokot A, Drmic D, et al. Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine. J Physiol Pharmacol. 2015;66:581–590. [PubMed] [Google Scholar]

Song, K., Han, H., Kim, S., & Kwon, J. (2020). Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. European Journal of Pharmacology, 869, 172891.

Sosne, G., Qiu, P., & Kurpakus-Wheater, M. (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology (Auckland, N.Z.), 1(3), 201.

Spurney, C. F., Cha, J., Sali, A., Pandey, G. S., Pistilli, E., Guerron, A. D., Gordish-Dressman, H., Hoffman, E. P., & Nagaraju, K. (2010). Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PLoS ONE, 5(1), e8976.

Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. doi: https://10.1002/brb3.1726. [DOI] [PMC free article] [PubMed] [Google Scholar]

Wang X-Y, Qu M, Duan R, et al. Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells. Neurosci Bull. 2019;35:167–170. [DOI] [PMC free article] [PubMed] [Google Scholar]

Wu H, Wei M, Li N, et al. Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable

Gastric Pentadecapeptide BPC 157. Drug Devel Ther. 2020;14:5599–5610. [DOI] [PMC free article] [PubMed] [Google Scholar]

Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. [DOI] [PubMed] [Google Scholar]

Xing, Y., Ye, Y., Zuo, H., & Li, Y. (2021). Progress on the Function and Application of

Thymosin β4. Frontiers in Endocrinology, 12, 767785.

Bioregulatory medicine is a total body (and mind) approach to health and healing that aims to help facilitate and restore natural human biological processes. It is a proven, safe, gentle, highly effective, drugless, and side-effect-free medical model designed to naturally support the body to regulate, adapt, regenerate, and self-heal. BRMI is a non-commercial 501(c)(3) foundation and will expand and flourish with your support. Our goal is to make bioregulatory medicine a household term.

This article is for informational purposes only and is not intended to be a substitute for the direct care of a qualified health practitioner who oversees and provides unique and individualized care. The information provided here is to broaden our different perspectives and should not be construed as medical advice, diagnosis, or treatment.